Benefits
Stress-related fatigue reduction
In a double-blind crossover trial, standardized Rhodiola rosea (the SHR-5 extract, not Rhodiolife specifically) reduced a Fatigue Index in physicians working night shifts. Rhodiolife shares the rosavin and salidroside markers used in that trial, but Rhodiolife itself has not been tested for fatigue, and no student-exam trial is among the studies cited here.
Mild anxiety and mood support
Standardized Rhodiola extract supports reductions in self-reported anxiety, stress, anger, confusion, and depression scores in mildly anxious adults, helping people feel calmer and more even-keeled during demanding periods.
Generalized anxiety symptom support
Pilot clinical work in adults with generalized anxiety symptoms has shown clinically meaningful reductions on the Hamilton Anxiety Rating Scale over 10 weeks of daily Rhodiola rosea extract, supporting an anxiolytic role for the adaptogen.
Mental performance when fatigued
In a night-duty trial, standardized Rhodiola rosea reduced a Fatigue Index measured across cognitive and perceptive tasks, meaning less mental decline when tired. A separate 14-day trial in mildly anxious adults measured cognition directly and found no improvement, so Rhodiola should not be expected to raise cognitive performance in people who are not fatigued.
Mechanism of action
HPA axis modulation
Rosavins and salidroside modulate hypothalamic-pituitary-adrenal axis reactivity, blunting excessive cortisol responses to acute stressors and supporting faster post-stress recovery.
Monoamine oxidase modulation
Rhodiola constituents inhibit monoamine oxidase A and B in vitro, reducing breakdown of serotonin, dopamine, and norepinephrine — a plausible mechanism behind the antidepressant and anxiolytic effects.
Mitochondrial energy support
Salidroside activates AMPK and supports mitochondrial biogenesis, helping maintain ATP production efficiency under stress and contributing to the anti-fatigue effects observed clinically.
Clinical trials
Randomized controlled trial of standardized Rhodiola rosea extract (Vitano®, 2 × 200 mg/day) versus no-treatment control for 14 days in 80 mildly anxious participants. Outcomes: self-reported anxiety, stress, anger, confusion, depression, total mood, and cognition.
80 mildly anxious adults. 14 days.
Rhodiola rosea significantly reduced self-reported anxiety, stress, anger, confusion, and depression, and improved total mood versus the no-treatment control. No cognitive differences were observed. Supports the use of standardized Rhodiola for sub-clinical anxiety symptoms.
10-week open-label pilot study of standardized Rhodiola rosea extract (Rhodax, 340 mg daily) in 10 adults with generalized anxiety symptoms. Outcome: Hamilton Anxiety Rating Scale (HARS).
10 adults with generalized anxiety symptoms. 10 weeks.
HARS scores decreased significantly from baseline to endpoint, with symptom improvement comparable in magnitude to several first-line treatment trials. Small open-label design limits inference, but supports a clinical signal for Rhodiola in generalized anxiety symptom reduction.
Randomized double-blind placebo-controlled crossover study of SHR-5 standardized Rhodiola rosea extract (~170 mg, repeated low-dose regimen) in 56 healthy physicians on night duty for two weeks. Outcomes: Fatigue Index across cognitive and perceptive tasks.
56 healthy physicians on night-shift duty. 2 weeks.
Rhodiola rosea significantly reduced overall mental fatigue (Fatigue Index) versus placebo across complex perceptive and cognitive tasks. Foundational evidence for the adaptogen's anti-fatigue and stress-buffering effects in working professionals.